VKTX实时信号 | 通过Getagraph.com最大化利润

出售 5224 min ago

@ $68.57

发出时间: 26 Apr 2024 @ 03:47

回报率: 8.38%

上一信号: Apr 25 - 22:34

上一信号: 购买

回报率: 4.68 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):
Our systems believe the stock currently is overvalued by 3.18% compare to its pairs and should correct downwards.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders...

Stats
今日成交量	3.54M
平均成交量	6.50M
市值	8.13B
EPS	$-0.250 ( 2024-04-24 )
下一个收益日期	( $-0.240 ) 2024-07-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-80.77
ATR14	$5.11 (6.88%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Mancini Marianna	Buy	31 667	Common Stock, par value $0.00001 per share
2024-03-27	Mancini Marianna	Sell	16 610	Common Stock, par value $0.00001 per share
2024-03-27	Lian Brian	Buy	221 667	Common Stock, par value $0.00001 per share
2024-03-27	Lian Brian	Sell	153 948	Common Stock, par value $0.00001 per share
2024-03-27	Zante Greg	Buy	31 667	Common Stock, par value $0.00001 per share

INSIDER POWER
10.07
Last 100 transactions
Buy: 2 960 710 \| Sell: 2 536 561

相关性 (AI algo v.1.1b): Overvalued: -3.18% $71.98 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: 0.98 (very strong)

短: 0.32 (neutral)

Signal:(67) Neutral

Viking Therapeutics Inc 相关性

10 最正相关
CFFE	0.97
ARIZ	0.966
EMLD	0.96
ARTEU	0.96
AIB	0.958
GENQ	0.956
FTII	0.956
GDST	0.955
ACLS	0.955
BRAC	0.954

10 最负相关
SMFL	-0.968
NCBS	-0.963
MYSZ	-0.96
PIII	-0.958
CREG	-0.955
BCAB	-0.95
SPCX	-0.949
KTTA	-0.948
TRIT	-0.947
VFF	-0.947

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Viking Therapeutics Inc 相关性 - 货币/商品

0.03
( neutral )

0.78
( moderate )

0.00
( neutral )

0.35
( neutral )

-0.26
( neutral )

0.03
( neutral )

Viking Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-292 000 (0.00 %)
EPS:	$-0.910

FY	2023
营收:	$0
毛利润:	$-292 000 (0.00 %)
EPS:	$-0.910

FY	2022
营收:	$0
毛利润:	$-291 000 (0.00 %)
EPS:	$-0.880

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.757

Financial Reports:

No articles found.

Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.